The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting.
Uhi Toh
No relevant relationships to disclose
Nobutaka Iwakuma
No relevant relationships to disclose
Mai Mishima
No relevant relationships to disclose
Miki Takenaka
No relevant relationships to disclose
Ryuji Takahashi
No relevant relationships to disclose
Mina Furukawa
No relevant relationships to disclose
Teruhiko Fujii
No relevant relationships to disclose
Etsuyo Ogo
No relevant relationships to disclose
Shino Nakagawa
No relevant relationships to disclose
Maki Tanaka
No relevant relationships to disclose
Tetsuro Sasada
No relevant relationships to disclose
Kyogo Itoh
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose